SUMMARY -Infl ammation, apoptosis and extracellular remodeling play signifi cant roles in cardiovascular disease (CVD) underlying the major causes of mortality in renal patients. In 19 pre-dialysis patients, 21 dialysis patients and 20 control subjects, the concentrations of pentraxin-3, galectin-3, MMP-9 and TIMP-1 were determined by ELISA. CVD risk was calculated according to the Framingham risk score algorithm. Pentraxin-3 was increased in renal patients compared to healthy controls (p<0.001). In contrast, galectin-3 was reduced in hemodialysis patients compared to pre-dialysis patients and controls (p<0.001). In addition, MMP-9 and TIMP-1 were elevated in renal patients compared to controls (p<0.01 and p<0.001, respectively). Logistic regression analyses disclosed associations of galectin-3, MMP-9, pentraxin-3 and glomerular fi ltration with calculated CVD risk score. Combined testing of pentraxin-3, galectin-3, MMP-9 and glomerular fi ltration rate can discriminate renal patients with high and low risk of a coronary event.
Introduction
Chronic kidney disease (CKD) represents a signifi cant health problem worldwide. Th e increasing prevalence of hypertension and diabetes as the main factors will further enhance the number of patients developing end-stage renal disease (ESRD) 1 . Cardiovascular disease (CVD), chronic low-grade infl ammation and protein-energy wasting are present in a large proportion of patients with advanced CKD 2 , and each of these factors independently predicts their outcome 2, 3 . Pentraxin-3, an acute-phase protein, plays an important role in the regulation of infl ammatory reactions, clearance of apoptotic cells and resistance to pathogens 2 . Tong et al. 2 showed that pentraxin-3 has a predictive value for mortality in CKD.
Progressive renal disease is a consequence of disequilibrium between the increased synthesis of extracellular matrix components and their decreased degradation, which occurs as a result of imbalanced matrix metalloproteinase (MMP) activities and their tissue inhibitors (TIMP), leading to nephron loss 4 . Increased infl ammation and oxidative stress enhance MMP expression and activity, thus increasing the prevalence of numerous diseases including atherosclerosis, nephritis and fi brosis 5 . MMP-9 is a zinc-dependent enzyme involved in tissue remodeling which includes degradation of extracellular matrix components, as well as the processing of non-matrix substrates 4 . In contrast, TIMP-1 is a specifi c endogenous inhibitor that binds MMP-9 and suppresses its activity 5 . Galectin-3, a molecule with diverse biological activities, might play a role within the complex maze of connections that link infl ammation, extracellular matrix remodeling and apoptosis. Th e former is a multifunctional lectin with a broad range of actions including anti-adhesion, binding advanced glycation endproducts (AGE), regulation of gene expression and controlling cell proliferation and death 6 . However, more recent evidence suggests that galectin-3 is an anti-apoptotic and anti-fi brotic agent, thus functioning to prevent further CKD development 7 . Due to its diversity of actions, the role of galectin-3 in progressive renal disease remains controversial.
From 1948, the Framingham study strived to identify common factors contributing to CVD over a long period of time. Hypertension, smoking, hyperlipidemia and age were found to be independent risk factors for CVD. Th e study employed the Framingham risk score (FRS) algorithm in order to predict an acute coronary event within the next 10 years 8 . Our present study aimed to assess circulating pentraxin-3, galectin-3, MMP-9 and TIMP-1 concentrations in diff erent stages of CKD, in both dialysis and non-dialysis patients, as well as in a control group. We also assessed association between plasma concentrations of pentraxin-3, galectin-3, MMP-9, TIMP-1 and estimated glomerular fi ltration rate (eGFR) with the FRS. Using pentraxin-3, galectin-3 and MMP-9/ TIMP-1 as markers which are in various ways involved in the pathology of renal disease and eGFR as a common indicator of kidney function, we tried to fi nd out whether there is diff erence in the FRS between diff erent stages of kidney failure.
Material and Methods

Subjects
Th is study included 40 renal disease patients from the Department of Nephrology, Clinical Centre of Serbia, Belgrade. Nineteen of them were pre-dialysis patients with CKD stage 2-4, not requiring hemodialysis (10 men and 9 women, mean age 53.5±18.54 years), while the remaining 21 patients (15 men and 6 women, mean age 53.8±14.41 years) were ESRD patients receiving dialysis [average duration 52.3 (26.8-102.4) months]. Th e original kidney diseases in CKD and ESRD patients were: chronic glomerulonephritis (n=6), nephroangiosclerosis (n=3), diabetic nephropathy (n=9), polycystic kidney disease (n=3), other (n=14) and unknown diagnosis (n=5). ESRD patients on thrice-weekly maintenance hemodialysis treatment (each time 4-5 hours) received a bicarbonate-based solution using polyamide and polysulfone low-fl ux or high-fl ux membranes. CKD patients with some form of glomerulonephritis as the main disease received corticosteroids or other immunosuppressive therapy according to general protocols. Th e control group consisted of 20 healthy subjects free of infl ammation, neurological dysfunction, history of CVD, renal, gastrointestinal, pulmonary, hepatic and oncologic disease not taking any prescribed medication.
Th e study was planned according to the ethical guidelines detailed in the Declaration of Helsinki. Th e Ethics Committee of the Clinical Center of Serbia and the Ethics Committee of the Faculty of Pharmacy, University of Belgrade evaluated and approved the study protocol. Informed consent was voluntarily obtained from all study participants.
Sample collection
Blood samples were collected after a 12-h fasting period. Serum was separated by centrifugation at 1500xg for 10 min, aliquoted and stored at -80 °C for up to one month until analysis. Blood was collected from patients immediately prior to dialysis.
Biochemical analyses
Total cholesterol and triglycerides were measured by standard automated enzymatic methods (Biosystems S.A., Barcelona, Spain) using ILab 300 + (Instrumentation Laboratory, Milan, Italy). Plasma HDL-C was determined using a direct assay (Biosystems S.A., Barcelona, Spain), whereas LDL-C cholesterol concentration was calculated using the Friedewald formula. Serum urea, creatinine, uric acid, total proteins and glucose were measured by routine laboratory methods (Bio Systems S.A., Barcelona, Spain) with an ILab 300 + analyzer. Th e eGFR was calculated using the Modifi cation of Diet in Renal Disease equation (MDRD) 9 .
ELISA
Serum concentrations of pentraxin-3, galectin-3, MMP-9 and TIMP-1 were determined by ELISA (R&D systems, Minneapolis, USA).
Framingham risk score calculation
Th e risk of CVD was calculated according to the FRS algorithm. Calculation of FRS was based on age, gender, smoking, blood pressure, total and HDL cholesterol as coronary risk factors. According to this score, all study participants were divided into three categories indicating low (<10%), medium (10%-20%) and high (>20%) risk of an acute coronary event within the next 10 years 8 .
Statistical analyses
Data are shown as mean ± standard deviation (SD) for normally distributed variables, or as geometric mean with 95% confi dence interval (95% CI) or as median and interquartile range for parameters not normally distributed. Diff erences among continuous variables were assessed using ANOVA or Kruskal-Wallis test, where appropriate. Analyses of categorical variables used the χ 2 -test for contingency tables. A value of p<0.05 was considered statistically signifi cant. In renal patients, the possible independent association between CVD risk and concentrations of galectin-3, pentraxin-3, MMP-9, TIMP-1 and eGFR was tested by binary logistic regression. Th e low-risk category was used as the reference group and was coded 0, while the high-risk group was coded 1. Th ree models were tested, as follows: Model 1 -pentraxin-3, galectin-3, MMP-9; Model 2 -pentraxin-3, galectin-3, glomerular fi ltration; and Model 3 -pentraxin-3, galectin-3, MMP-9, glomerular fi ltration. We constructed receiver operating characteristic (ROC) curves with the predictive probabilities from diff erent logistic regression models and performed pair-wise comparisons using the areas under the ROC curve (AUCs). According to the Hosmer and Lemeshow 10 rules for the logistic models, the discriminative abilities of the models were classifi ed per their AUC values as poor: (0.5≤AUC<0.7), acceptable (0.7≤AUC<0.8), excellent (0.8≤AUC<0.9) or outstanding (AUC ≥0.9) 10 For all analyses, the SPSS software (IBM ® SPSS ® version 22.0) was used.
Results Table 1 contains data on the subjects involved in this study and the results of biochemical analyses within the study groups (CKD-pre-dialysis patients, ESRD-dialysis patients and healthy controls). Decreased HDL-C (p<0.01) was evident in renal patients in comparison with healthy subjects. HDL-C was also signifi cantly lower in patients on dialysis (p<0.01). As expected, dialysis patients showed increased creatinine compared to pre-dialysis patients and controls. Serum concentrations of urea, creatinine and uric acid were signifi cantly higher in dialysis patients compared with pre-dialysis patients and controls. Diff erences in serum concentrations of total and LDL-C, triglycerides and fasting glucose between the groups were not statistically signifi cant (p>0.05). As expected, after taking into account all the results and analyzing the FRS algorithm, we found that renal disease patients had an increased risk of CVD development as compared to the control group, but there was no diff erence between the subgroups of renal patients.
Diff erences between pre-dialysis patients, dialysis patients and controls in the concentrations of pentraxin-3, galectin-3, MMP-9 and TIMP-1 are shown in Table 2 . Pentraxin-3 was signifi cantly increased in both groups of renal patients compared to controls (p<0.001). In contrast, galectin-3 was reduced in dialysis patients compared to the pre-dialysis and control groups (p<0.001). In addition, MMP-9 and TIMP-1 were elevated in renal patients compared to controls (p<0.01 and p<0.001, respectively).
In the present study, we investigated diff erent models in order to discriminate renal patients with high and low risk of CVD according to FRS values. To accomplish this, we constructed ROC curves with predictive probabilities and calculated AUCs (Table 3) . Only combinations between parameters with significant AUC values are reported. According to the Hosmer and Lemeshow rule, the AUC (0.732) for Model 2, which included pentraxin-3, galectin-3, MMP-9 and glomerular fi ltration, was acceptable. However, a pair-wise comparison of ROC curves showed that this improvement was not statistically signifi cant (p=0.453). Data are expressed as mean ± standard deviation; creatinine, triglycerides, HDL-C and LDL-C are presented as geometric mean and 95% confi dence interval (95% CI) derived from log-normal values; urea and glucose are shown as median and interquartile range; continuous variables were compared using ANOVA or Kruskal-Wallis test; Tukey's post hoc test was used for subgroup diff erences; categorical variables (gender) were compared using the χ 2 -test; FRS = Framingham risk score; LDL-C = low density cholesterol; HDL-C = high density cholesterol; eGFR = glomerular fi ltration rate; p = statistical diff erences between control subjects and renal patients; a statistically signifi cant diff erences between pre-dialysis and dialysis patients; b statistically signifi cant diff erences between pre-dialysis patients and control group; c statistically signifi cant diff erences between dialysis patients and control group Table 2 . Concentrations of pentraxin-3, MMP-9 and TIMP-1 are presented as geometric mean and 95% confi dence interval derived from lognormal values; galectin-3 concentration is median and interquartile range; continuous variables were compared using ANOVA or KruskalWallis test; categorical variables (gender) were compared using the χ 2 test; p = statistical diff erences between control subjects and renal patients; a statistically signifi cant diff erences between pre-dialysis and dialysis patients; b statistically signifi cant diff erences between pre-dialysis patients and control group; c statistically signifi cant diff erences between dialysis patients and control group 
Concentrations of pentraxin-3, galectin-3, matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1)
Discussion
Infl ammation in CKD is one of the most important factors involved in initiating and progression of atherosclerosis, which is the main cause of morbidity and mortality in these patients. Increased infl ammation in renal pathology may be explained by the presence of other illnesses, elevated oxidative stress, bioincompatible dialyzers, urinary tract infections, and increased production/decreased clearance of infl ammatory cytokines 11 . Pentraxin-3 (PTX3), an acute phase protein, is produced by a variety of tissues and cells, as well as in the human renal cortex, medulla, glomeruli, and in the mesangial cells after stimulation with interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α) 12 . In our study, we showed that both patient groups had higher PTX3 than controls, with the highest concentration tending to be in dialysis patients (Table 2) . Increased PTX3 levels could be explained as a consequence of impaired kidney function and its enhanced synthesis and release in peripheral tissues 13 . Given that multiple studies have reported a negative correlation between PTX3 concentration and glomerular fi ltration in CKD 2, 14 , increased PTX3 could also be explained by its decreased clearance. PTX3 is a prototype of long pentraxins; a large molecule with molecular weight of 40.6kD characterized by a pentameric structure, which can result in increased retention during uremia 15 . A recent fi nding also suggests that PTX3 can induce morphological changes in mesangial cells, causing contraction and consequential reduction in the glomerular fi ltration area 16 . Furthermore, considering that these patients are permanently in a low-grade infl ammatory state, PTX3 could be involved in the innate immune response against pathogens, regulation of infl ammatory reactions, as well as in the removal of apoptotic cells 11 . In addition, our present study found markedly higher PTX3 concentration in patients undergoing dialysis (Table 2) . A pathological uremic milieu can cause enhanced release of IL-1β and TNF-α which induce production of PTX3 leading to continuous systemic low-grade infl ammation 17 . In agreement with our fi ndings is a study by Rusnati et al., which suggested that PTX3 expression was probably related to the processes of matrix deposition, angiogenesis and tissue repair 18 . Mounting evidence indicates that besides dyslipidemia, infl ammation and oxidative stress, extensive vascular remodeling contributes to the initiation and/or progression of CKD 19 . Matrix metalloproteinases and their TIMPs play an important role in maintaining the equilibrium between the formation and degradation of extracellular matrix (ECM) proteins 4 . Considering that the main eff ect of MMPs is degradation, it is well documented that in the early stages of kidney disease MMPs contribute to the breakdown of collagen type IV, the primary component of the ECM in glomerular basal membranes and mesangial matrix 20 . Our results indicated that pre-dialysis and dialysis patients had elevated concentrations of MMP-9 and TIMP-1 in comparison with controls (Table 2) , probably indicating that increased production of MMP-9 would result in excessive degradation of the ECM 21 . In contrast, incorrect timing for MMP inhibition during disease has been described with increased TIMP inhibition and subsequent decreased MMP activity, resulting in deposition of ECM in CKD and renal fi brosis 22, 23 . Increased levels of TIMP-1 were present in the patients suggesting that prolonged increased inhibition of MMP-9 could have been a factor for the development of fi brosis at a later period 23 . Previous fi ndings suggested that oxidative stress and infl ammation could be additional factors that induce MMP-9 expression and synthesis 18, 24 . As MMP-9 is released by neutrophils, monocytes and macrophages during the course of an infl ammatory response, increased infl ammation found in these patients could be a possible reason for elevated levels of MMP-9 and consequently TIMP-1 in dialysis and non-dialysis groups compared with controls. Further evidence also indicates that this imbalance between MMP-9 activity and appropriate TIMP-1 inhibition is associated with atherosclerotic development in CKD, as well as with disease progression 22 . Galectin-3 is a multifunctional β-galactosidebinding lectin responsible for many physiological and pathophysiological processes in the human body. It is involved in organogenesis, in the production of proinfl ammatory cytokines, the induction of oxidative stress, in alternative macrophage activation and in apoptosis 6 . However, recent evidence suggests protective eff ects of galectin-3. It enhances matrix remodeling, protection from fi brosis, and it is a receptor for AGE 25 . AGEs are glycated proteins or lipids present in many diff erent cell types and implicated in both micro-and macrovascular complications of diabetes, which are the main causes of CKD 26 . Galectin-3 has been recently identifi ed as an AGE receptor with high affi nity for binding, internalization and degradation of AGE 25 . In contrast to Receptor for Advanced Glycation End products (RAGE) receptors, which promote tissue damage through the induction of oxidative stress, galectin-3 removes AGE and prevents renal injury 27 . In the present study, we showed that dialysis patients had decreased galectin-3 compared to pre-dialysis patients and controls, implicating reduced AGE removal from tissue and circulation. In addition, it has been demonstrated that AGEs promote ECM deposition via regulation of various cytokines 26 . We assume that decreased galectin-3 results in elevated AGE levels and enhanced uptake by RAGE receptors, subsequently followed by increased oxidative stress and ECM deposition.
As mentioned above, ECM remodeling is a critical process in renal pathology. Besides MMP and TIMP equilibrium, which is important for balancing synthesis, deposition and degradation, it has been suggested that galectin-3 may represent a second major pathway impacting on ECM remodeling 1 . Cuttle et al. demonstrated that tissue architecture of the interstitial matrix in galectin-3-defi cient mice was more disorganized compared to wild type mice 28 . Th is fi nding implies that the anti-fi brotic eff ects of galectin-3 might be a consequence of enhanced ECM turnover. Our data demonstrate decreased galectin-3 in dialysis patients compared to pre-dialysis patients and controls, presumably indicating poor regulation of ECM organization in dialysis patients. In an animal fi brosis model, the severity was signifi cantly increased in galectin-3-deficient mice compared to wild type counterparts after unilateral ureteral obstruction 29 . Th is indicates the potential protective role of galectin-3 in attenuation of fi brosis severity during advanced stages of chronic kidney injury. Intracellular galectin-3 is a well-known anti-apoptotic factor, primarily localized in the cytoplasm where it inhibits activation of caspases, in a similar way as Bcl-2. It has also been shown that galectin-3 enhances recovery of tubular cells through limitation of apoptosis and promotion of cell proliferation during chronic kidney injury. Taking into consideration all these facts, decreased galectin-3 concentration in dialysis patients might indicate increased apoptotic processes, which lead to more profound chronic renal failure 29 . Th e analysis of ROC curves and AUCs revealed the combination of galectin-3, pentraxin-3, MMP-9 with glomerular fi ltration rate to be the best discriminator between patients with low and high risk of CVD development. As expected, FRS confi rmed previous fi ndings that renal patients had an increased risk of a coronary event compared with healthy subjects. We also found that in addition to glomerular fi ltration, galectin-3, pentraxin-3 and MMP-9 could be potent predictors of high CVD risk in renal patients. Considering these fi ndings, we assume that diff erentiation of renal patients with low and high CVD risk could be the potential clinical signifi cance of this research. Th e relatively small number of renal patients in our study may represent a limitation. Further studies with larger sample sizes are needed to re-evaluate our current observations.
Conclusion
Our results provide a robust link between infl ammation, ECM organization and apoptosis, which forms the basis for future in-depth studies. Long-term low-grade infl ammation represented with increased pentraxin-3 can induce an imbalance between MMP-9 and TIMP-1 leading to fi brosis in end-stage renal patients. Th is misbalance can be potentiated by decreased galectin-3 in dialysis patients. Our results also confi rmed the diverse roles of galectin-3, which besides its proinfl ammatory role also protects renal tubules from chronic injury by limiting apoptosis and fi brosis. All the above-mentioned interactions contribute to the increased risk of CVD, which is the leading mortality cause in renal disease patients.
